Full-Service Outsourcing Restructuring for Emerging CRO in Rare Disease Space

Orchestrated end-to-end business operations restructuring for an emerging CRO expanding its FSO footprint in rare disease trials. By streamlining protocol-to-submission workflows, consolidating vendor management, implementing risk-based monitoring frameworks, and optimizing cross-functional governance, we cut trial delivery timelines by 18%, reduced overhead by 22%, and strengthened single-point accountability—positioning the organization to compete effectively against larger players in high-value, niche indications.